6jpj: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Crystal structure of FGF401 in complex of FGFR4== | |||
<StructureSection load='6jpj' size='340' side='right'caption='[[6jpj]], [[Resolution|resolution]] 2.64Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6jpj]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6JPJ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6JPJ FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.638Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=FGF:~{N}-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-methanoyl-6-[(4-methyl-2-oxidanylidene-piperazin-1-yl)methyl]-3,4-dihydro-2~{H}-1,8-naphthyridine-1-carboxamide'>FGF</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6jpj FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6jpj OCA], [https://pdbe.org/6jpj PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6jpj RCSB], [https://www.ebi.ac.uk/pdbsum/6jpj PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6jpj ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Biochemical and structural studies provide information on the mode of action of FGF401 as a selective, reversible covalent inhibitor of FGFR4. Kinase and proliferation assays reveal that FGF401 has the ability to overcome gatekeeper mutations in FGFR4. | |||
Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4.,Zhou Z, Chen X, Fu Y, Zhang Y, Dai S, Li J, Chen L, Xu G, Chen Z, Chen Y Chem Commun (Camb). 2019 May 1. doi: 10.1039/c9cc02052g. PMID:31041948<ref>PMID:31041948</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: Chen | <div class="pdbe-citations 6jpj" style="background-color:#fffaf0;"></div> | ||
[[Category: | |||
[[Category: | ==See Also== | ||
*[[Fibroblast growth factor receptor 3D receptor|Fibroblast growth factor receptor 3D receptor]] | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | |||
[[Category: Chen X]] | |||
[[Category: Chen Y]] | |||
[[Category: Zhou Z]] | |||
Latest revision as of 11:04, 17 October 2024
Crystal structure of FGF401 in complex of FGFR4Crystal structure of FGF401 in complex of FGFR4
Structural highlights
Publication Abstract from PubMedBiochemical and structural studies provide information on the mode of action of FGF401 as a selective, reversible covalent inhibitor of FGFR4. Kinase and proliferation assays reveal that FGF401 has the ability to overcome gatekeeper mutations in FGFR4. Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4.,Zhou Z, Chen X, Fu Y, Zhang Y, Dai S, Li J, Chen L, Xu G, Chen Z, Chen Y Chem Commun (Camb). 2019 May 1. doi: 10.1039/c9cc02052g. PMID:31041948[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||